Close Menu

MDxHealth

NEW YORK (GenomeWeb News) – Sorenson Genomics and MDxHealth today separately announced they have each received accreditation from the College of American Pathologists.

Merck KGaA and MDxHealth have extended an existing personalized medicine research collaboration so that the drug firm will fund the development, regulatory activities, and commercial launch of a companion diagnostic being advanced by MDxHealth for an investigational glioblastoma

NEW YORK (GenomeWeb News) – MDxHealth today announced its collaborative agreement with Merck KGaA has been expanded to include the continued development and worldwide commercialization of MDxHealth's PredictMDx for Glioblastoma test.

This story has been updated to reflect that MDxHealth completed its private placement on June 29.
NEW YORK (GenomeWeb News) – MDxHealth has successfully completed a private placement that raised €10 million ($12.4 million).

NEW YORK (GenomeWeb News) – Molecular diagnostics company MDxHealth today said that revenues for the first quarter more than doubled year over year as its Pharmaco Diagnostic business grew 203 percent.

NanoString Launches Second Validation Study for PAM50
[This article has been updated from a previous version to correct details about NanoString's PAM50 test.]

NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – MDxHealth today reported that its fourth-quarter 2011 revenues increased 48 percent year over year, driven by its pharmaco diagnostic business.

FDA Greenlights Quest's PML Risk Test for Patients Prescribed Tysabri

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.